25. Hyperlipidemia: Prevalence, Monitoring, Management, Interactions with Immunosuppressive Agents, and Follow-Up

  1. Bipin N Savani MD
  1. Dara L Eckerle Mize1,
  2. Shubhada Jagasia1 and
  3. Jeffrey B Boord2

Published Online: 6 SEP 2013

DOI: 10.1002/9781118473306.ch25

Blood and Marrow Transplantation Long-Term Management: Prevention and Complications

Blood and Marrow Transplantation Long-Term Management: Prevention and Complications

How to Cite

Eckerle Mize, D. L., Jagasia, S. and Boord, J. B. (2013) Hyperlipidemia: Prevalence, Monitoring, Management, Interactions with Immunosuppressive Agents, and Follow-Up, in Blood and Marrow Transplantation Long-Term Management: Prevention and Complications (ed B. N. Savani), John Wiley & Sons, Ltd, Oxford, UK. doi: 10.1002/9781118473306.ch25

Editor Information

  1. Professor of Medicine,Director, Long Term Transplant Clinic, Hematology and Stem Cell Transplantation Section, Vanderbilt University Medical Center, Nashville, TN, USA

Author Information

  1. 1

    Division of Diabetes, Endocrinology & Metabolism, Vanderbilt University Medical Center, Nashville, TN, USA

  2. 2

    Division of Cardiovascular Medicine, Vanderbilt Heart and Vascular Institute, Nashville, TN, USA

Publication History

  1. Published Online: 6 SEP 2013
  2. Published Print: 1 OCT 2013

ISBN Information

Print ISBN: 9781118473405

Online ISBN: 9781118473306

SEARCH

Keywords:

  • hematopoietic stem cell transplantation;
  • hyperlipidemia;
  • dyslipidemia;
  • GVHD;
  • immunosuppressant therapy;
  • hypercholesterolemia;
  • hypertriglyceridemia;
  • statin;
  • cholesterol

Summary

This chapter discusses mechanisms, evaluation, and management of hyperlipidemia in patients following hematopoietic stem cell transplantation (HSCT). While the foundations of therapy and medications used are similar to those used to treat hyperlipidemia in the general population, there are several important factors which must be considered in these patients prior to treatment. Immunosuppressive drug therapy is a common contributor to posttransplant dyslipidemia. The patient's cardiovascular disease risk, pattern and degree of dyslipidemia, timing of HSCT, history of graft-versus-host disease, disease-related prognosis, and use of immunosuppressive therapy must be considered in order to safely determine a treatment regimen. Proper selection of lipid agents is also crucial to minimize risk of drug interactions and adverse drug effects. All patients should have evaluation of lipid status prior to transplant, and regular monitoring posttransplantation.